Evidence map›Paper›PMID 34913149›Full record

Trial reportChinese journal of integrative medicine2022

Effect of Jiuwei Zhuhuang Powder on Cough Resolution in Children with Upper Respiratory Tract Infections: A Multicenter Randomized Controlled Trial.

Hui Luo, Gui-Hua Song, Xiao-Jian Ma, Meng-Meng Sun, Man Zhang, Jian-Rong Xie, Shao Peng

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Chinese journal of integrative medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Hui LuoInstitute for Tibetan Medicine, China Tibetology Research Center, Beijing, 100101, China.
Gui-Hua SongDepartment of Pediatrics, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450000, China.
Xiao-Jian MaDepartment of Pediatrics, Huaihe Hospital of Henan University, Zhengzhou, 450000, China.
Meng-Meng SunDepartment of Pediatrics, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450000, China.
Man ZhangDepartment of Pediatrics, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 475000, China.
Jian-Rong XieSchool of Statistics, Renmin University of China, Beijing, 100872, China.
Shao PengDepartment of Pediatrics, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 475000, China. Pengshaodh630@126.com.
First Affiliated Hospital of Henan University · CNFirst Affiliated Hospital of Zhengzhou University · CNChina Tibetology Research Center · CNHenan University Huaihe Hospital and Huaihe Clinical Institute · CNRenmin University of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the effectiveness of Jiuwei Zhuhuang Powder (JWZH), a Tibetan patent medicine in treating upper respiratory tract infection (URTI) associated cough in children.

methodsThe study was a multicenter, randomized, open-label, controlled trial. A total of 142 children aged 2 to 14 years old, with URTI-associated cough within 48 h of onset, were randomly assigned to two groups at a 1:1 ratio by computer-generated randomization sequence. Children were treated with JWZH (1 to 1.5 g, twice to thrice daily) in the treatment group or conventional treatment (Pediatric Paracetamol, Artificial Cow-bezoar and Chlorphenamine Maleate Granules, 0.25 to 1 g, thrice daily) in the control group for 5 days. The primary endpoints were the time to cough resolution and 4-day cough resolution rate. The secondary endpoints were the daily improvement in symptom scores and cough resolution rate during the study period.

resultsA total of 138 children were included in the intention-to-treat analysis, with 71 cases in the treatment group and 67 cases in the control group. Compared with the conventional treatment, the children receiving JWZH had a shorter time to cough resolution [hazard ratio, 2.10; 95% confidence interval (CI), 1.29-3.40; P=0.003]. The median time to cough resolution for children receiving JWZH was shorter than that of the conventional treatment (2 days vs. 3 days; P<0.001). The 4-day cough resolution rate in the JWZH group was higher than that of the control group (94.4% vs. 74.6%; risk difference: 19.8%, 95% CI: 8.1%-31.5%; relative risk: 1.265, 95% CI: 1.088-1.470; P=0.001). There were no statistically significant differences in the improvement of other symptoms caused by URTI (P>0.05). Adverse events was reported in 5.6% (4/71) and 4.5% (3/67) in participants of JWZH and PPACCM groups (P>0.05), respectively, which were all mild and resolved without treatment.

conclusionJWZH seemed to be a safe and effective therapy for URTI-associated cough in children. (Trial registration No. ChiCTR2000039421).

Indexed as

CoughRespiratory Tract InfectionsChildDrugs, Chinese HerbalHumansNonprescription DrugsPowdersDrugs, Chinese HerbalNonprescription DrugsPowderszhuhuangchild coughJiuwei Zhuhuang Powderrandomized controlled trialTibetan medicineupper respiratory tract infection

Identifiers

PMID34913149
PMCPMC8672858
OpenAlexW4200410341

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.